Somerville, Mass.-based Mass General Brigham named Paul Anderson, MD, PhD, chief academic officer, a role he has filled on an interim basis since Jan. 1.
Dr. Anderson has already made meaningful contributions to Mass General, including leading several transformative initiatives focused on elevating research and teaching systemwide. He focuses on supporting enhanced collaboration for the greatest impact on patients.The health system has a research budget exceeding $2 billion, and has more than 14,000 researchers who contribute to more than 2,700 active clinical trials.
Dr. Andreson launched the Gene Cell Therapy Institute, an innovation hub with more than 400 researchers and clinicians advancing gene and cell therapy. He was among the leaders who launched the Gene Lay Institute of Immunology and Inflammation, bringing together Brigham, Mass General and Harvard Medical School researchers to advance immunotherapy.
"We believe that in the next five to 10 years, many new therapies for our patients will come from gene and cell therapy discoveries and research endeavors across our hospitals," said Dr. Anderson in a news release. "I'm thrilled to be able to put our vision into practice by supporting our investigators in moving discoveries toward new treatments for patients here and around the world."
Previously, Dr. Anderson was academic dean for Mass General Brigham at Harvard Medical School. In his new role, he will maintain oversight of human subject affairs, clinical trials office, research management, data science, personalized medicine, graduate medical education and more.